A New Frontier in Data Protection

Biomemory has officially launched DNA Shield, a specialized repository service engineered to store essential digital information in synthetic DNA. By leveraging the physical properties of molecules, the company aims to protect critical data from the evolving threats posed by cybercriminals and advanced technologies, such as sophisticated artificial intelligence.


The solution addresses the growing need to safeguard "cold data," which accounts for approximately 60% of global data volume. This includes immutable information such as biometric records, passwords, proprietary intellectual property, cryptographic keys, and historical institutional archives.


The Advantages of Molecular Storage

Unlike traditional digital storage, DNA Shield functions as an offline, airgapped system. Because the information is encoded into a physical molecule, it requires no power source for maintenance and offers significant advantages in terms of density and longevity:

  • Durability: Potential data lifespan of up to 150 years.
  • Density: DNA-based storage is roughly a million times denser than conventional magnetic media.
  • Security: By keeping data offline and isolated from networked systems, it remains invulnerable to remote cyberattacks.

Laurent Guengant, CEO of Biomemory, emphasized the strategic shift the product represents:

«DNA Shield is the moment Biomemory moves from proving a science to delivering a commercial product. Organizations need a way to hold their most critical digital assets... somewhere no single vendor, cloud, or system can reach, and to prove it still works over time.»


Availability and Commercial Rollout

The launch of this service follows Biomemory's acquisition of the Boston-based pioneer Catalog Technologies in early 2026. This move positions Biomemory as a leader in the nascent field of "Molecular IT."


Currently, the service is in its pilot phase, running from mid-October 2026 until mid-2027. Following this trial period, the company plans to transition to a full-scale commercial launch. According to Vincent Franceschini, Vice President of Product Management at Biomemory, the transition is a significant milestone: «DNA Shield is built on the same molecular platform we have spent years industrializing, but it is the first time we are asking a customer to rely on it operationally rather than as a research demonstration.»


For organizations looking to secure their most sensitive assets, subscription plans for the DNA Shield service begin at €10,000 per month, with application windows currently open for pilot participants.